Non-Enzymatic Glycation in Alzheimer’s and Parkinson’s Disease: A Molecular Approach to Pathology and Recent Advances

Year : 2024 | Volume : 02 | Issue : 02 | Page : 36 41
    By

    Mohammad Nadeem Khan,

  1. Assistant Professor, Department of Pharmacology, Clinical Pharmacology, Sri Aurobindo Medical College & PG Institute, Sri Aurobindo University, Near MR-10, Bhawaresala, Sanwer Road, Indore, Madhya Pradesh, India

Abstract

Non-enzymatic glycation, a biochemical process by which reducing sugars spontaneously bind to proteins, leads to the formation of advanced glycation end-products (AGEs), which have emerged as critical contributors to the pathogenesis of several neurodegenerative diseases, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD). The accumulation of AGEs can significantly alter protein structure, stability, and function, triggering a cascade of detrimental effects, including increased oxidative stress, heightened neuroinflammation, and the promotion of pathological protein aggregation—hallmarks associated with the progression of these debilitating disorders. This article delves into recent molecular and mechanistic insights into how glycation drives proteomic alterations in AD and PD, examining its impact on neuronal integrity and cellular homeostasis. Additionally, it highlights significant advancements in modern analytical techniques, such as mass spectrometry and advanced proteomic tools, that have been pivotal in elucidating glycation-induced modifications at the molecular level. Emphasis is placed on emerging therapeutic strategies aimed at targeting glycation pathways, including the inhibition of AGE formation, scavenging of reactive intermediates, and the enhancement of cellular repair mechanisms, offering promising avenues for innovative and effective intervention in these neurodegenerative diseases.

Keywords: Advanced glycation end-products (AGEs), Alzheimer’s disease (AD), Parkinson’s disease (PD), AGE-RAGE signaling, protein misfolding, oxidative stress, neuroinflammation, proteomics

[This article belongs to International Journal of Molecular Biotechnological Research ]

How to cite this article:
Mohammad Nadeem Khan. Non-Enzymatic Glycation in Alzheimer’s and Parkinson’s Disease: A Molecular Approach to Pathology and Recent Advances. International Journal of Molecular Biotechnological Research. 2024; 02(02):36-41.
How to cite this URL:
Mohammad Nadeem Khan. Non-Enzymatic Glycation in Alzheimer’s and Parkinson’s Disease: A Molecular Approach to Pathology and Recent Advances. International Journal of Molecular Biotechnological Research. 2024; 02(02):36-41. Available from: https://journals.stmjournals.com/ijmbr/article=2024/view=183835


References

1. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015—The global impact of dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International.
2. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10(S7):S10–S17. doi:10.1038/nm1066.
3. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia. 2014;44(2):129–146. doi:10.1007/s001250000161.
4. Rabbani N, Thornalley PJ. Advanced glycation endproducts in the pathogenesis of chronic kidney disease. Kidney Int. 2018;93(4):803–813. doi:10.1016/j.kint.2017.11.034.
5. Ahmed N. Advanced glycation endproducts—role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67(1):3–21. doi:10.1016/j.diabres.2004.09.004.
6. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: Identification of a cellular activation mechanism. Exp Neurol. 2009;171(1):29–45. doi:10.1006/exnr.2001.7741.
7. Kuhla B, Lüth HJ, Haferburg D, Boeck K, Arendt T, Münch G. Methylglyoxal, glyoxal, and their detoxification in Alzheimer’s disease. Ann N Y Acad Sci. 2005;1043(1):211–216. doi:10.1196/annals.1333.024.
8. Chen K, Maley J, Ralph M, Shneider BL, Krasna MJ. Glycation increases amyloid-beta aggregation and contributes to Alzheimer’s disease pathology. Neurobiol Aging. 2010;31(7):1025–1033. doi:10.1016/j.neurobiolaging.2009.09.008.
9. Vicente MH, Szego ÉM, Oliveira LM, Breda C, Darendelioglu E, de Oliveira RM, et al. Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Brain. 2017;140(5):1399–1419. doi:10.1093/brain/awx056.
10. Lüth HJ, Münch G, Arendt T. Aberrant glycosylation in Alzheimer’s disease: A pivotal role for brain oxidative stress. Eur J Neurosci. 2005;22(6):1552–1564. doi:10.1111/j.1460-9568.2005.04364.x.
11. Ott C, Jacobs K, Haucke E, Navarrete SA, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411–429. doi:10.1016/j.redox.2013.12.016.
12. Walker DG, Lue LF, Serrano G, Beach TG. Gene expression profiling of amyloid-beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging. 2001;22(6):957–966. doi:10.1016/S0197-4580(01)00306-2.
13. Dong Y, Li X, Cheng J, Hou L, Zhang J, Liu Y. Neuroinflammation as a target for treatment of Parkinson’s disease. Neurochem Res. 2020;45(5):1045–1056. doi:10.1007/s11064-020-02995-7.
14. Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO. Mass spectrometric detection of early glycation products on human serum albumin. Anal Chem. 2017;79(5):2556–2564. doi:10.1021/ac061919d.
15. Poulsen MW, Hedegaard RV, Andersen JM, De Courten B, Bügel S, Nielsen J, et al. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol. 2013;60:10–37. doi:10.1016/j.fct.2013.06.052.
16. Nielsen ML, Savitski MM, Zubarev RA, Schmid M. Proteomic and structural analysis of glycated proteins. J Proteom Res. 2015;14(3):1195–1203. doi:10.1021/pr5009713.
17. Ahmed N, Thornalley PJ, Rabbani N. Protein glycation, oxidative stress and ageing. Biochem J. 2020;477(6):1153–1162. doi:10.1042/BCJ20190455.
18. Chen J, Xu H, Li M, Li G. A novel molecular dynamics simulation for the interactions between amyloid-beta peptide and AGEs. J Mol Struct. 2018;1160:356–365. doi:10.1016/j.molstruc.2018.02.034.
19. Thornalley PJ, Rabbani N, Ahmed N. Advances in therapeutic inhibition of advanced glycation endproducts. Biochem Pharmacol. 2021;189:114240. doi:10.1016/j.bcp.2020.114240.
20. Chen J, Liu Q, Zhang R. Inhibition of advanced glycation end-product formation as a strategy for managing neurodegeneration. Front Pharmacol. 2019;10:1072. doi:10.3389/fphar.2019.01072.
21. Yan SD, Schmidt AM. Receptor for advanced glycation end-products (RAGE) as a therapeutic target: Mapping the path forward. Neurotherapeutics. 2016;13(2):223–238. doi:10.1007/s13311-016-0405-2.
22. Zhao L, Smith MA. RAGE and Alzheimer’s disease: Targets for therapeutic intervention. Aging Dis. 2018;9(5):958–970. doi:10.14336/AD.2017.1105.
23. Uribarri J, Cai W, Sandu O, Vlassara H. Dietary advanced glycation endproducts and their role in health and disease. Adv Nutr. 2015;6(4):463–471. doi:10.3945/an.115.008433.
24. Liu S, Zhao J, Li X, Wang Y. Dietary polyphenols and their anti-glycation effects: Potential therapeutic roles in neurodegenerative diseases. Food Chem. 2020;323:126791. doi:10.1016/j.foodchem.2020.126791.
25. Bennett RE, Krishnamurthy S. Advances in high-throughput screening for glycation-targeted therapies in neurodegenerative diseases. Curr Neuropharmacol. 2023;21(2):189–202. doi:10.2174/1570159X216662301230928.

Regular Issue Subscription Review Article
Volume 02
Issue 02
Received 08/11/2024
Accepted 15/11/2024
Published 18/11/2024
Publication Time 10 Days
314

Login


My IP

PlumX Metrics